Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) shares fell 14.8% during trading on Wednesday. The stock traded as low as $0.9010 and last traded at $1.04. 429,398 shares traded hands during trading, a decline of 59% from the average daily volume of 1,049,645 shares. The stock had previously closed at $1.22.
Virios Therapeutics Price Performance
The stock has a 50 day simple moving average of $1.62 and a two-hundred day simple moving average of $1.98. The company has a market cap of $20.03 million, a PE ratio of -3.85 and a beta of 1.58.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing antiviral therapies for conditions it believes may be associated with the activation of latent herpesviruses. The company’s research has centered on the potential role of viral reactivation in chronic diseases and related inflammatory symptoms.
Virios’ lead investigational product candidate has been IMC-1, a fixed-dose combination of famciclovir, an antiviral medication, and celecoxib, an anti-inflammatory drug.
Further Reading
- Five stocks we like better than Virios Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
